A New Drug for Head and Neck Cancer

Oncology is a field that specifically fights tumors.
The earthlings at the Fred Hutchinson Cancer Re-
search Center made another ground-breaking dis-
covery. Their thorough research unmasked a pot-
ential new therapy for some of the complicated-
to-handle neck and head cancers.

They did so after utilizing a method that searches
for genes that tumor cells rely on to live. Dr. Edu-
ardo Mendez, Chiang Xu, and Michael Koa are m-
embers of that research team. Head and neck can-
cer occurs through cells lined in the mouth, throat,
larynx, & nose.

On occasions, it will go through salivary glands. Y-
es, tobacco utilization does accelerate the chanc-
es of getting it and so does HPV. Disfigurement c-
an happen because the tumors are that hardcore.
They certainly have the power to decrease the abi-
lity to talk, swallow, & breath.

The treatments that are currently used can beco-
me helpless. It depends on the location of the tu-
mors. So surgery can cause even more disfigur-
ement. The most utilized chemotherapy therapy
(cisplatin) has a lot of toxic, side effects.

Yes, those caring folks at the center knows that
the new drug is urgently needed. They sincerely
want to eliminate cancer but also want to ensu-
re that the patients are thriving & so functional.

The team focus on cells that conceal mutatio-
ns in the tumor-suppressor p53. Those mutatio-
ns are in head & neck cancers commonly. Can-
cer starts when cells either rev up genes that pu-
shes the gas way over on replication, or lose ge-
nes that assist cells regarding applying the brak-
es.

The p53 gene usually becomes a brake verses r-
apid cell growth. When tumor cells lose a gene,
it's hard to find drugs for what is missing. The r-
esearch team received an award in the amount
of 4 million dollars.

Researcher Kay Gurley, Dr. Carla Grandor, Dr.
Eduardo Mendez, and Christopher Kemp use a
skill they mastered over the years. They named
it functional genomics and it searches through
100's or 1000's of genes.

It looks for the closed ones that stops the grow-
th of tumor cells, but not the healthy cells. They
also use it for breast and pancreatic cancer. Sci-
entist go to other genes that interact with p53 to
find better ways to target treatments.

The results showed thirty-nine potential drug targ-
ets. Wee 1 is the guilty gene that became the ta-
rget of the cancer therapy called AZD1775. The
pharmaceutical establishment AstraZeneca owns
that drug.

They tested the therapy on a mouse & it slowed
down tumor growth drastically. Oncologist Laura
Chow & SCCA's oncology team will launch an e-
phase trial this fall season. AstraZeneca will pay
for it.